speb/financial-data huggingface dataset:
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 67337000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 67337000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Change In Inventory: 552790000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -27924000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Change In Payable: -569125000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -818806000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -863065000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -169011000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock: 453173000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 453173000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 19899064000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 19899064000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 43000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 3293285000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 3293285000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 10766530000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 2596511000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Current Assets: 13221672000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 13221672000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 50940000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 50940000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt: 2927967000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 2927967000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 2978907000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 2978907000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 6570495000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 6570495000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 117383000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 117383000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation: 869040000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 869040000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 869040000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 228158000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 869040000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 228158000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 90680692.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 90698973.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Diluted EPS: 30.04
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 9.74
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 2724048000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 883408000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 3490000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 3490000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 507000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — EBIT: 3875859000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — EBIT: 1212030000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — EBITDA: 4744899000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — EBITDA: 1440188000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — End Cash Position: 67337000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: 654349000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 2310462000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 2310462000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: -1137389000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -507000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 157200000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill: 17806000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 17806000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 1002201000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 1002201000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 5782117000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 5782117000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 20481635000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 20481635000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Gross Profit: 10384215000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 3041259000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense: 268964000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 65833000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 268964000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 65833000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Interest Income: 70962000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 70962000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -245115000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 70961000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Inventory: 5875793000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 5875793000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 23939614000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 23939614000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -4124754000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 235834000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 235834000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Investments In Other Ventures Under Equity Method: 56572000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Investments In Other Ventures Under Equity Method: 56572000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 43000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 1000000000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 841460000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 841460000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 116689000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 116689000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 1112583000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 1112583000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1229272000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1229272000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 1000000000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 56572000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 56572000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 81178000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 81178000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 14218280000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 14218280000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Minority Interests: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Minority Interests: 0.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 43000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Net Debt: 3973213000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Debt: 3973213000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -16933000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Net Income: 2724048000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income: 883408000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 2724048000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 883408000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 2724048000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 883408000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 2724048000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 883408000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 2724048000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 883408000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 3606895000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 2724048000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 883408000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Intangibles Purchase And Sale: -418409000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Net Interest Income: -268964000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -65833000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 228339000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: 1278608000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 1000000000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -268964000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -65833000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Other Financing Charges: -1000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Other Investing Changes: 14222000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Net PPE: 14334486000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 14334486000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -4020374000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: 278608000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 18896863000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 18896863000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1284041000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 1284041000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 81178000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 81178000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 140276000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 140276000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 4744899000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 1440188000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Normalized Income: 2724048000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 883408000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 3301394000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Operating Income: 3774667000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Income: 1228104000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Operating Revenue: 21150745000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 5637770000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 90634624.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 90634624.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 2000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 2000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 35839000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 35839000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 17305000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 17305000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 984395000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 984395000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: 183772000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: -3000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: -3000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Non Current Liabilities: 1000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 1000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 84259000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 8596000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 4120913000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 1151343000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Payable: 199462000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 199462000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Properties: 11041200000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 11041200000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 103710000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 103710000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 488388000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 488388000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Other Special Charges: -76000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Payables: 2992705000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Payables: 2992705000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Pension And Employee Benefit Expense: 19345000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 117383000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 117383000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 926063000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 926063000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Pretax Income: 3606895000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 1146197000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 12814000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of Intangibles: -418409000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -4020374000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 2262797000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 2262797000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 10766530000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 2596511000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 869040000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 228158000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 11728000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 11728000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Research And Development: 328321000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 6332000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 6332000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 13233115000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 13233115000.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 228338000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 790015000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 947215000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Share Issued: 90634624.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 90634624.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Special Income Charges: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 19899064000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 19899064000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 18896863000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 18896863000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Tax Provision: 882847000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 262789000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.24
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.23
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Taxes Receivable: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Taxes Receivable: 0.00
AARTIPHARM.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -645266000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Total Assets: 29064051000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 29064051000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 21011647000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 21011647000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Total Debt: 4208179000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 4208179000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 19899064000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 19899064000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Total Expenses: 17376078000.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 4409666000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 9164987000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 9164987000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 15842379000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 15842379000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2594492000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2594492000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 11449000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 11449000.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
AARTIPHARM.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Work In Process: 1302534000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 1302534000.00
AARTIPHARM.NS balance_sheet (annual, 2025-03-31) — Working Capital: 6651177000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 6651177000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 1443354000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 3861909000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 90661538.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 5.46
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 1694054000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 227922000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 227922000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 90661538.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 5.46
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 495012000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — EBIT: 722496000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — EBITDA: 950418000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 2167855000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 67949000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 67949000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Minority Interests: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income: 495012000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 495012000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 495013000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 495012000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 495012000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 495013000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -67949000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -67949000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 950418000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 495012000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Income: 724501000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 3861909000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 15955000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 802864000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 654547000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 1694054000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 227922000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 159534000.00
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.24
AARTIPHARM.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 3137408000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 1586091000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 4183348000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 2854022000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 4700830000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 1873490000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 90659416.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 3.08
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 699094000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 453206000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 321936000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 556127000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 453206000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 20462056000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 1605026000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 2097762000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 13262980000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 157188000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 3881369000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 4038557000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 8106226000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 119565000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 247692000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 247692000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 90659416.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 3.08
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 279231000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — EBIT: 493574000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — EBITDA: 741266000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 17806000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 1145159000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 15609624000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 2085586000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 106652000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 106652000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 6205882000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 26350740000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 1873490000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 541906000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 2007315000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 2549221000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 66837000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Minority Interests: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net Debt: 5566748000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income: 279231000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 279231000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 279231000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 279231000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 279231000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 279231000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -106652000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -106652000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 15609624000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 19316897000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 1315267000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Non Current Prepaid Assets: 300170000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 741266000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 279231000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Income: 499495000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 4183348000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 90641224.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 1604727000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 278653000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 20008850000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Intangible Assets: 1127353000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 391975000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Non Current Liabilities: -1000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: 503000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 904277000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Properties: 14004598000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Receivables: 5433000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 234191000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Otherunder Preferred Stock Dividend: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Payables: 2854022000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Pretax Income: 386922000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 2097762000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 247692000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Share Issued: 90641224.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Special Income Charges: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 20462056000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 19316897000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Provision: 107691000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.28
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 189981000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Assets: 32659045000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 22469371000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Debt: 6587778000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 20462056000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Total Expenses: 3683853000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 12196989000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 19396065000.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 4090763000.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2025-09-30) — Working Capital: 5156754000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 1859263000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 4322727000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 90653308.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 5.29
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 1726557000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 286177000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 286177000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 90653308.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 5.29
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 479556000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — EBIT: 754484000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — EBITDA: 1040661000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 2596170000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 125796000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 125796000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Minority Interests: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income: 479556000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 479556000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 479556000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 479556000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 479556000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 479556000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -125796000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -125796000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 1068610000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 500875176.83
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Income: 736907000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 4322727000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: -3712000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 1139307000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 628688000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1726557000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 286177000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -27949000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -6629823.17
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 149132000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.24
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 3585820000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -27949000.00
AARTIPHARM.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -27949000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — +Operating Expense: 6865275000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 1976568000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — +Total Revenue: 18194425000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 5826440000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 3345393000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 3345393000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 5833244000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 5833244000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 2292752000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 2292752000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 90662844.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 90688576.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Basic EPS: 19.27
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 6.74
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 67337000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -4483133000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 687269000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 687269000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 453289000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 453289000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 85303000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 85303000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 96159000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 96159000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -362590000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -805645000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: 26367000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Change In Payable: 702459000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Change In Receivables: -992765000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -1069584000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 17966000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock: 453289000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 453289000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 21246047000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 21246047000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 116000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 3052109000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 3052109000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 8348324000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 2830218000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Current Assets: 13972919000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 13972919000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 165509000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 165509000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt: 4998230000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 4998230000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 5163739000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 5163739000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 9375701000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 9375701000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 112205000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 112205000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation: 1043351000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 1043351000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 1043351000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 281560000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 1043351000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 281560000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 90757039.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 90688576.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Diluted EPS: 19.25
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 6.74
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 1747073000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 611241000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 0.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — EBIT: 2798240000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — EBIT: 985416000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — EBITDA: 3841591000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — EBITDA: 1266976000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — End Cash Position: 85303000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 1705822000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: -1863818000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill: 0.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 0.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 1238872000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 1238872000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 17066634000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 17066634000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Gross Profit: 9846101000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 2996222000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense: 469028000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 168630000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 469028000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 168630000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -387345000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 21390000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Inventory: 6403077000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 6403077000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 28102391000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 28102391000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -4307171000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 2292752000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 2292752000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 116000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 521760000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 521760000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 1858114000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 1858114000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 2379874000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 2379874000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 78518000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 78518000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Minority Interests: 0.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 0.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 116000.00
AARTIPHARM.NS balance_sheet (annual, 2026-03-31) — Net Debt: 6771041000.00
AARTIPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 6771041000.00
AARTIPHARM.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 332084000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Net Income: 1747073000.00
AARTIPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income: 611241000.00
AARTIPHARM.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 1747073000.00